Oxford Biomedica has developed highly efficient packaging and producer cell lines, which enable scalable and cost-effective manufacturing.
Lentiviral vectors are commonly manufactured using the transient process of transfecting plasmid DNAs into production cells. However, manufacturing large quantities of material for late-phase clinical trials and product commercialisation can remain a challenge using this process.
We have generated suspension and adherent-based stable packaging and producer cell lines using an inducible system.
Packaging cell lines stably integrate some of the components of the lentiviral system into the cell genome (envelope (e.g. VSV-G), Gag/Pol and Rev). Producer cell lines integrate all components (envelope (e.g. VSV-G), Gag/Pol, Rev and vector genome).
LentiStableTM is the result of more than 15 years of optimisation work. Our cutting-edge, automated technologies enable us to streamline production, minimise process risks and reduce costs. Our proprietary robotic system, CassiusTM, uses state-of-the-art automation to screen and isolate up to 3000 clones thereby enabling the identification of high titre lentiviral vectors producing clones in significantly reduced timelines.
From packaging to producer cell lines
Our expert team can design your producer cell line in a significantly reduced timescale:
Higher lentiviral vector titre is achieved using our stable producer cell line compared to a traditional transient transfection process.
Stewart et al., Gene Therapy (2009), Development and inducible EIAV-based lentiviral vector packaging and producer cell line
Stewart et al., Human Gene Therapy (2011), A Stable Producer Cell Line for the Manufacture of a Lentiviral Vector for Gene Therapy of Parkinson’s Disease
Intellectual Property: US 6,969,598 - "Methods for producing high titre vectors and compositions used in such methods"